Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Expands By 604.6%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 214,200 shares, a growth of 604.6% from the March 31st total of 30,400 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is presently 0.2 days.

Sonoma Pharmaceuticals Stock Performance

NASDAQ SNOA remained flat at $0.16 during trading on Friday. The company’s stock had a trading volume of 108,630 shares, compared to its average volume of 362,434. Sonoma Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $1.52. The firm’s fifty day moving average price is $0.15 and its 200 day moving average price is $0.21.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Thursday, February 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. The company had revenue of $3.14 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 41.24% and a negative return on equity of 58.93%. On average, sell-side analysts predict that Sonoma Pharmaceuticals will post -0.89 earnings per share for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.